Idiopathic Pleuroparenchymal Fibroelastosis clinical trials at UCSF
1 in progress, 0 open to new patients
Sorry, not currently recruiting here
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.
San Francisco, California and other locations